NSCLC, non–small cell lung cancer; PP, polypharmacy; ECOG-PS, Eastern Cooperative Oncology Group–Performance Status; BMI, body mass index; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; CCI, Charlson Comorbidities Index; GRIm-Score, Gustave Roussy Immune Score.

^a Non–small cell carcinoma, not other specified (n = 8), adenosquamous carcinoma (n =1), combined histology composed of adenocarcinoma and small-cell carcinoma (n= 1).

^b Squamous cell carcinoma (n = 2), non–small cell carcinoma, not other specified (n = 1), adenosquamous carcinoma (n =1), pleomorphic carcinoma (n = 1), poorly differentiated carcinoma (n =1).

^c Exon 18 G719X (n = 5), exon 21 L861Q (n = 2), exon 20 insertion (n = 1), exon 18 G719X + exon20 S768I, exon 19 del + exon 21 L858R (n = 1), exon 20 S768I + exon 21 L858R (n = 1).

^d Exon 18 G719X (n = 3), exon 20 T790M + exon 21 L858R (n = 2), exon 18 G719X + exon 19 deletion (n = 1), exon 18 G719X + exon21 L858R (n = 1).